Who Exports Methotrexate from India — 353 Suppliers Behind a $34.9M Market
India's methotrexate export market is supplied by 353 active exporters who collectively shipped $34.9M across 3,806 shipments. CIPLA LIMITED leads with a 52.8% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and INTAS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 73.0% of total export value, reflecting a concentrated market structure.
Top Methotrexate Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading methotrexate exporter from India, holding a 52.8% share of the $34.9M market across 3,806 shipments from 353 exporters. The top 5 suppliers — CIPLA LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, INTAS PHARMACEUTICALS LIMITED, ZYDUS LIFESCIENCES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED — collectively control 73.0% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (52.8%), EUGIA PHARMA SPECIALITIES LIMITED (8.6%), INTAS PHARMACEUTICALS LIMITED (4.4%), ZYDUS LIFESCIENCES LIMITED (3.7%), ALEMBIC PHARMACEUTICALS LIMITED (3.6%).
Top Methotrexate Exporters from India
Ranked by export value · 353 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED METHOTREXATE TABLETS 2.5 MGIMUTREX 2.5MG TAB METHOTREXATE 2.5MGMETHOTREXATE SPC 2.5 TABLETS (METHOTREXA | $18.4M | 13 | 52.8% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED METHOTREXATE TABLETS USP 2.5 MG 100'S -METHOTREXATE TABLETS USP 2.5 MG -METHOTREXATE 50MG/ML, 0.50ML 1PFSAC-CAN | $3.0M | 3 | 8.6% |
| 3 | INTAS PHARMACEUTICALS LIMITED METHOTREXATE TABLETS 2.5 MGARX-METHOTREXATE 10 TABLETS ..METHOTREXATE TABLETS 2.5 MG INV.QTY.95 | $1.5M | 11 | 4.4% |
| 4 | ZYDUS LIFESCIENCES LIMITED METHOTREXATE TABLETS USP 2.5 MG 100'S -METHOREX 2.5MG TABS 10X10METHOTREXATE TABLETS BP-2.5MG BRAND:.INT | $1.3M | 2 | 3.7% |
| 5 | ALEMBIC PHARMACEUTICALS LIMITED METHOTREXATE TABLETS USP 2.5 MG 100'S -METHOTREXATE TABLETS USP 2.5 MG -METHOTREXATE TABLETS 2.5 MG (METHOTREXAT | $1.3M | 1 | 3.6% |
| 6 | NAPROD LIFE SCIENCES PRIVATE LIMITED ALLTREXALLTREX NOSALLTREX METHOTREXATE TABLETS BP 2.5MG | $1.2M | 8 | 3.3% |
| 7 | VENUS REMEDIES LIMITED METHOTREXATE SPC 2.5 TABLETS (METHOTREXAMETHOTREXATE SPC 2.5 TABLETSMETHOREX 2.5MG TABS 10X10 | $921.0K | 22 | 2.6% |
| 8 | FRESENIUS KABI ONCOLOGY LIMITED METHOTREXATE SPC 2.5 TABLETS (METHOTREXAMETHOTREXATE SPC 2.5 TABLETSALLTREX | $771.5K | 15 | 2.2% |
| 9 | APRAMEYA PHARMACHEM PRIVATE LIMITED | $743.7K | 2 | 2.1% |
| 10 | CADILA HEALTHCARE LIMITED METHOTREXATE TABLETS USP 2.5 MG 100'S -METHOTREXATE TABLETS USP 2.5 MG -METHOTREXATE TABLETS 2.5 MG (METHOTREXAT | $468.2K | 1 | 1.3% |
| 11 | INTAS PHARMACEUTICALS LTD METHOTREXATE TABLETS 2.5 MGARX-METHOTREXATE 10 TABLETS ..METHOTREXATE TABLETS 2.5 MG INV.QTY.95 | $439.3K | 2 | 1.3% |
| 12 | MYLAN LABORATORIES LIMITED | $420.7K | 2 | 1.2% |
| 13 | KHANDELWAL LABORATORIES PRIVATE LIMITED METHOREX 2.5MG TABS 10X10ALLTREXMETHOTREXATE TABLETS BP-2.5MG BRAND:.INT | $248.1K | 8 | 0.7% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Methotrexate exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| EUGIA PHARMA SPECIALITIES LIMITED | Warning Letter, August 20 | Unknown | Unknown | Not verified | FDA issued a warning letter citing CGMP violations at Unit III facility. |
| ZYDUS LIFESCIENCES LIMITED | Approved | Unknown | Unknown | Multiple approvals | Received USFDA approval for enzalutamide tablets in October 2024. |
| INTAS PHARMACEUTICALS LIMITED | Approved | Unknown | Yes | 89 approvals as of 2018 | EU GMP certified; FDA approvals for multiple products. |
| ALEMBIC PHARMACEUTICALS LIMITED | Approved | Unknown | Unknown | 223 approvals as of 2025 | Received multiple USFDA approvals between 2024 and 2025. |
| CIPLA LIMITED | Approved | Unknown | Unknown | Unknown | Acquired InvaGen Pharmaceuticals and Exelan Pharmaceuticals in 2015. |
TransData Nexus reviewed the regulatory standing of 5 leading Methotrexate exporters from India. 4 hold US FDA facility approvals, 0 maintain WHO-GMP certification, and 1 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Methotrexate sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a pivotal center for the production of active pharmaceutical ingredients (APIs). The city contributes approximately 40% of the country's bulk drug output, underscoring its significance in the pharmaceutical supply chain. The establishment of Hyderabad Pharma City aims to further consolidate this position by creating a comprehensive ecosystem for pharmaceutical manufacturing and research.
The presence of numerous API manufacturers in Hyderabad suggests a robust infrastructure capable of supporting Methotrexate production. This concentration of expertise and facilities positions the city as a strategic source for bulk Methotrexate supplies.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being central to this output.
Vadodara hosts major pharmaceutical companies like Alembic Pharmaceuticals, which specializes in formulations. This specialization indicates a strong capacity for producing finished Methotrexate products, aligning with the region's emphasis on formulations.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai's strategic location and well-established port facilities facilitate efficient international distribution. The region's infrastructure supports the export of pharmaceutical formulations, including Methotrexate, to global markets.
The proximity to major ports and logistical hubs enhances the region's role in the global supply chain, ensuring timely and efficient delivery of pharmaceutical products.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is recognized for its favorable tax incentives, attracting numerous pharmaceutical manufacturers. This cluster has become a significant production hub, contributing to the overall capacity for drug manufacturing in India.
The tax benefits and supportive policies in this region have led to increased production capabilities, potentially including Methotrexate formulations.
5Sourcing Recommendations
- Diversify Supplier Base: Engage with manufacturers across multiple clusters to mitigate risks associated with regional disruptions.
- Leverage API Production in Hyderabad: Utilize Hyderabad's robust API manufacturing capabilities for sourcing bulk Methotrexate.
- Capitalize on Formulation Expertise in Gujarat: Partner with companies in Ahmedabad and Vadodara for high-quality Methotrexate formulations.
- Optimize Export Logistics via Mumbai: Utilize Mumbai's port facilities for efficient international distribution of Methotrexate products.
By strategically engaging with these pharmaceutical clusters, TransData Nexus can enhance its supply chain resilience and ensure a steady supply of Methotrexate to meet global demand.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Methotrexate exporters from India
Zydus Lifesciences Limited — Zydus receives USFDA approval for prostate cancer drug
Zydus Lifesciences received approval from the U.S. Food and Drug Administration (USFDA) to manufacture enzalutamide tablets, used for treating prostate cancer. The product will be manufactured at Zydus' facility in Ahmedabad. - IMPACT: This approval may enhance Zydus' oncology portfolio but is not directly related to Methotrexate exports.
Impact: This approval may enhance Zydus' oncology portfolio but is not directly related to Methotrexate exports.
Common Questions — Methotrexate Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which methotrexate supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 217 recorded shipments worth $18.4M. EUGIA PHARMA SPECIALITIES LIMITED (58 shipments) and INTAS PHARMACEUTICALS LIMITED (109 shipments) are also established high-volume exporters.
Q How many methotrexate manufacturers are there in India?
India has 353 active methotrexate exporters with a combined export market of $34.9M across 3,806 shipments to 148 countries. The top 5 suppliers hold 73.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for methotrexate from India?
Average FOB unit price: $24.53 per unit, ranging from $0.00 to $15947.47. Average shipment value: $9.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 353 verified Indian exporters of Methotrexate ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,806 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 148 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,806 Verified Shipments
353 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists